Regeneron Pharmaceuticals, Inc is a biotechnology company founded in 1988 by physician-scientists. The company invents, develops and commercializes life-transforming medicines for people with serious diseases, maintaining a relentless focus on scientific inquiry as a core part of its culture.
The company's technical work spans antibody discovery, genetics and genetic medicine. Its proprietary VelociSuite® technologies are used to produce optimized fully human antibodies and new classes of bispecific antibodies. Through the Regeneron Genetics Center® (RGC), the company applies data-powered insights to pioneer advances in genomic medicine.
Regeneron employs over 15,000 people globally, including more than 1,400 team members with MDs and/or PhDs. Its research-driven environment, with deep roots in both biotechnology and pharmaceuticals, provides a setting for engineers and scientists working at the intersection of large-scale data, computational methods and drug discovery.
